Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05161234 · ClinicalTrials.gov registry record
A Clinical Utility Study of PrismRA for Rheumatoid Arthritis
A clinical trial, sponsored by Scipher Medicine.
- Completed
- Registry status
- 613
- Enrollment target
NCT05161234: Completed study, sponsored by Scipher Medicine.
NCT05161234 is a clinical trial that has completed, run by Scipher Medicine. The registered enrollment target is 613 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05161234 has completed, sponsored by Scipher Medicine.
- COMPLETED
- Registry status
- 613 participants
- Enrollment target
Study Summary
A clinical utility study for PrismRA testing therapeutic response in patients with rheumatoid arthritis.
Primary Outcome
Proportion of moderate to severe disease activity patients that achieve measurable clinical outcomes therapeutic response after initiation of a non-csDMARD therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2023-12-06 |
What the finished NCT05161234 record still lists
NCT05161234 is an observational study that tracks outcomes without assigning an intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05161234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05161234 about?
NCT05161234 is a clinical study titled "A Clinical Utility Study of PrismRA for Rheumatoid Arthritis". A clinical utility study for PrismRA testing therapeutic response in patients with rheumatoid arthritis.
What is the current status of trial NCT05161234?
This trial is currently completed. The enrollment target is 613 participants. The study started on 2022-03-03. Estimated completion is 2023-12-06.
Who is sponsoring clinical trial NCT05161234?
This trial is sponsored by Scipher Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI